CEREN-3: Long-term Safety and Tolerability of Itepekimab in CRSwNP

Phase 3, randomised, double-blind trial of itepekimab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Sanofi. Primary endpoint: Incidence of treatment-emergent adverse events, adverse events of special interest, serious adverse events, AEs leading to death, and AEs leading to permanent treatment discontinuation at 72 weeks. Started Mar 2026; status: active, not recruiting.